AstraZeneca Restarts UK Expansion After ‘Strong’ Earnings

AstraZeneca has announced plans to invest £300m (US$408m) in the UK pharmaceutical sector, following a pause on large-scale projects in 2025.

The company pulled back investments in the country amid market instability over drug pricing and the availability of new medicines on the NHS.

On 29 April, it said it plans to invest into two existing locations: Cambridge – where it paused a £200m (US$272m) expansion – and Macclesfield – where it plans to invest an additional £100m (US$136m) into.

UK Prime Minister Keir Starmer says the investment will “future proof thousands of jobs”. He added that the investment was made possible thanks to the “pharmaceutical arrangement we have struck with the United States” during Prime Minister’s Questions on 29 April.

CEO Pascal Soriot said the company plans to build a “lab of the future” that will use digital and data tools to accelerate drug development at its Macclesfield site.

He thanked the government in a company statement, saying: “We would like to thank the British government for their efforts to improve access for patients, including four new approvals since the beginning of the year across the UK.

“We look forward to further enhancing the access and the reimbursement environment and build a strong life sciences sector."

More financially attractive with big pharma

In September 2025, AstraZeneca halted development of its £200m investment in Cambridge, which followed the abandonment of its £450m (US$612m) plan to invest in its vaccine manufacturing facility at Speke, Merseyside.

The company said the reason for the pause was due to cuts in government spending, despite months of negotiations.

This set of new investments is designed to create new scientific jobs in Macclesfield and transfer data analysis and molecular scientists into its new Rosalind Franklin office in Cambridge.

Discussing these investments, Susannah Streeter, Chief Investment Strategist at Wealth Club, says: "This is super encouraging and it does seem as though there is a sense of momentum returning to the pharmaceutical industry in the UK.”

She adds that the restart of the Cambridge expansion is “highly symbolic” and that it “demonstrates how the government has been working hard behind the scenes to try and make the UK more attractive to big pharma.”

Extending growth beyond 2030

On 29 April, AstraZeneca announced strong growth in its Q1 2026 earnings report, with revenues up 8% to US$15.3bn. In addition, company operating profit increased to 12%.

The company also saw a 16% growth in oncology and 15% rise in rare disease treatments.

Discussing the results in a company statement on Q1, Pascal praises the company’s performance, saying: “We delivered strong growth in Q1 2026, with total revenue above $15 billion, demonstrating our consistent commercial execution. 

“We are advancing through our catalyst‑rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key new molecular entities (NMEs).”

Cancer drugs now make up nearly half of AstraZeneca’s total sales. It states that some of its drugs individually could generate more than US$1bn in annual revenue by 2030, with the company aiming to achieve US$80bn in total sales by then.

Speaking on the company’s future ambitions, Pascal adds on the Q1 earnings call: “With a broad portfolio, a deep pipeline, and meaningful advances across multiple transformative technologies, we are well-positioned to extend growth beyond 2030.”